v3.25.2
Reportable Segment Information - Summary of Financial Information for Each Reportable Segment (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Sep. 30, 2024
Segment Reporting Information [Line Items]          
SALES $ 463 $ 544 $ 1,347 $ 1,591  
OPERATING INCOME (LOSS) (708) (61) (836) (57)  
DEPRECIATION EXPENSE 61 42 140 162  
AMORTIZATION EXPENSE 15 19 47 59  
EBITDA [1] (632) 0 (649) 164  
TOTAL ASSETS 4,621   4,621   $ 5,645
Intersegment Eliminations [Member]          
Segment Reporting Information [Line Items]          
SALES [2] (10) (12) (31) (36)  
Life Sciences [Member]          
Segment Reporting Information [Line Items]          
SALES 162 195 468 617  
OPERATING INCOME (LOSS) [3] (343) 43 (301) 125  
DEPRECIATION EXPENSE [4] 17 9 48 29  
AMORTIZATION EXPENSE 5 6 13 18  
EBITDA [1] (321) 58 (240) 172  
TOTAL ASSETS 1,531   1,531   1,778
Life Sciences [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
SALES 162 195 468 617  
Personal Care [Member]          
Segment Reporting Information [Line Items]          
OPERATING INCOME (LOSS) 25 31 64 59  
DEPRECIATION EXPENSE [5] 7 10 23 27  
AMORTIZATION EXPENSE 8 10 26 32  
EBITDA [1] 40 51 113 118  
TOTAL ASSETS 699   699   950
Personal Care [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
SALES 147 175 426 473  
Specialty Additives [Member]          
Segment Reporting Information [Line Items]          
SALES 131 150 380 429  
OPERATING INCOME (LOSS) [6] (345) 10 (343) (40)  
DEPRECIATION EXPENSE [7] 34 20 60 97  
AMORTIZATION EXPENSE 2 3 7 8  
EBITDA [1] (309) 33 (276) 65  
TOTAL ASSETS 1,048   1,048   1,516
Specialty Additives [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
SALES 131 150 380 429  
Intermediates [Member]          
Segment Reporting Information [Line Items]          
OPERATING INCOME (LOSS) 4 6 6 22  
DEPRECIATION EXPENSE 3 3 9 9  
AMORTIZATION EXPENSE 0 0 1 1  
EBITDA [1] 7 9 16 32  
TOTAL ASSETS 118   118   127
Intermediates [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
SALES 33 36 104 108  
Unallocated and Other [Member]          
Segment Reporting Information [Line Items]          
OPERATING INCOME (LOSS) [8] (49) (151) (262) (223)  
EBITDA [1] (49) $ (151) (262) $ (223)  
TOTAL ASSETS $ 1,225   $ 1,225   $ 1,274
[1] Excludes loss from discontinued operations, net of income taxes and other net periodic benefit loss. See the Statements of Condensed Consolidated Comprehensive Income (Loss) for applicable amounts excluded.
[2] Intersegment sales from Intermediates are accounted for at prices that approximate fair value. All other intersegment sales are accounted for at cost.
[3] Includes goodwill impairment of $375 million for Life Sciences for the three and nine months ended June 30, 2025.
[4] Depreciation includes accelerated depreciation of $8 million and $21 million for Life Sciences for the three and nine months ended June 30, 2025, respectively.
[5] Depreciation includes accelerated depreciation of $1 million for Personal Care for both the three and nine months ended June 30, 2024
[6] Includes goodwill impairment of $331 million for Specialty Additives for the three and nine months ended June 30, 2025.
[7] Depreciation includes accelerated depreciation of $19 million for Specialty Additives for both the three and nine months ended June 30, 2025, and $7 million and $55 million for the three and nine months ended June 30, 2024, respectively.
[8] Includes a $8 million gain on sale and a $183 million impairment charge related to the sale of the Avoca business for the nine months ended June 30, 2025, and a $99 million impairment charge related to the sale of the Nutraceuticals business for the three and nine months ended June 30, 2024, within the loss on acquisitions and divestitures, net caption of the Statements of Condensed Consolidated Income (Loss).